Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;16(6):687-694.
doi: 10.1016/j.jcf.2017.01.008. Epub 2017 Feb 10.

Pregnancy among cystic fibrosis women in the era of CFTR modulators

Sonya L Heltshe  1 , Emily M Godfrey  2 , Tatiana Josephy  3 , Moira L Aitken  4 , Jennifer L Taylor-Cousar  5
Affiliations

Pregnancy among cystic fibrosis women in the era of CFTR modulators

Sonya L Heltshe et al. J Cyst Fibros. 2017 Nov.

Abstract

Background: Little is known about how new therapies that partially correct the basic cystic fibrosis (CF) defect (ivacaftor and lumacaftor) might alter hormonal contraceptive effectiveness, impact pregnancy outcomes, or affect pregnancy timing. Examination of pregnancy rates among CF women during periods of CFTR modulator therapy initiation will provide foundation for further research in this area.

Methods: The Cystic Fibrosis Foundation Patient Registry was used to examine pregnancy rates and outcomes by genotype class before, during, and after the introduction of CFTR modulator therapies between 2005 and 2014.

Results: Among women with CF, ages 15-44years, there was a slight downward trend in annual pregnancy rates from 2005 to 2014 (2% reduction per year, p=0.041). Among women with G551D, pregnancy rates during phase 3 ivacaftor trial years was 14.4/1000 women-years compared to 34.0/1000 prior to the trial period (relative risk [RR]=0.65; 95% CI=0.43-0.96; p=0.011) and 38.4/1000 after drug approval in June 2012 (RR=1.52 post-approval compared to trial period; 95% CI=1.26, 1.83; p<0.001). Pregnancy outcomes did not significantly change between 2005 and 2014 for any genotype class.

Conclusion: Evidence of significantly increased numbers of pregnancies among women taking approved CFTR modulators is important because of the unknown risk to pregnancy and fetal outcomes. Increases may be temporary following pregnancy prevention during controlled clinical trials, or from altered perceptions about maternal survival with new approved treatments. As more women with CF become eligible to receive modulators, the CF community must study their effect on contraceptive efficacy and safety during pregnancy. With increased health and survival due to modulation, family planning topics will become more common in CF.

Keywords: G551D; Ivacaftor; Lumacaftor; Pregnancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Pregnancies among women with CF ages 15–44
Pregnancy rate (per 1000 woman-years) by year and genotype group. Thick gray line=rate for entire population; gray shaded region = 95% confidence interval for entire population; cyan line=R117H; blue line=Other; green line=G551D; red line=F508del homozygous; pink line =F508del heterozygous. Indicators for timing of Phase 3 trials in that genotype group (~10% of G551D women and ~5% of F508del homozygous women).
See this image and copyright information in PMC

References

    1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001. - PubMed
    1. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annual review of genetics. 1995;29:777–807. - PubMed
    1. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2014. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
    1. Simcox AM, Duff AJ, Morton AM, Edenborough FP, Conway SP, Hewison J. Decision making about reproduction and pregnancy by women with cystic fibrosis. British journal of hospital medicine. 2009;70(11):639–643. - PubMed
    1. Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med. 2007;13(6):537–540. - PubMed

MeSH terms